General description
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 2B4 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects Linker for activation of T-cells family member 1 (LAT). It targets an epitope within 18 amino acids from the N-terminal half.
Immunogen
KLH-conjugated linear peptide corresponding to 18 amino acids from the N-terminal half of human Linker for activation of T-cells family member 1 (LAT).
Application
Quality Control Testing
Evaluated by Western Blotting in EL4 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected LAT in EL4 cell lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected LAT in Jurkat and MOLT4 cell lysates.
Immunocytochemistry Analysis: A 1:1,000 dilution a representative lot detected LAT in EL4 cells.
Immunofluorescence Analysis: A 1:100 dilution a representative lot detected LAT in human tonsil tissue sections.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution a representative lot detected LAT in human tonsil tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Linker for activation of T-cells family member 1 (UniProt: O43561; also known as 36 kDa phospho-tyrosine adapter protein, pp36, p36-3, LAT) is encoded by the LAT gene (Gene ID: 27040) in human. LAT is a single-pass type III membrane protein with a short extracellular domain (aa 1-4), a transmembrane domain (aa 5-27), and a cytoplasmic domain (aa 28-262). It is expressed in thymus, T-cells, NK cells, and mast cells. It is required for T-cell antigen receptor (TCR)- and pre-TCR-mediated signaling, both in mature T-cells and during their development. It is also involved in low affinity immunoglobulin gamma Fc region receptor III (FCGR3)-mediated signaling in natural killer cells and in high affinity immunoglobulin epsilon receptor (FCER1)-mediated signaling in mast cells. It couples activation of these receptors and their associated kinases with distal intracellular events such as mobilization of intracellular calcium stores, protein kinase C activation, MAPK activation, and cytoskeletal reorganization. LAT undergoes phosphorylation on its tyrosine residues by ZAP70 upon TCR activation. It is one of the most prominently tyrosine-phosphorylated proteins detected following TCR engagement. Palmitoylation of Cys-26 and Cys-29 shown to be essential for its raft targeting and efficient phosphorylation. Phosphorylated form is shown to interacts directly with the regulatory subunit of phosphoinositide 3-kinase and the SH2 domains of GRB2, GRAP, GRAP2, PLC 1 and PLC 2. Mutations in LAT gene have been linked to immunodeficiency 52, an autosomal recessive disorder that is characterized by T-cell abnormalities, resulting in severe combined immunodeficiency and recurrent infections from infancy. Five isoforms of LAT have been described that are produced by alternative splicing. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Keller, B., et al. (2016). J. Exp. Med. 213(7); 1185-1199; Zhang, W., et al. (1998). Immunity. 9(2); 239-246).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
0.3 mg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.